Golodirsen Patent Expiration
Golodirsen is Used for treating Duchenne Muscular Dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping. It was first introduced by Sarepta Therapeutics Inc
Golodirsen Patents
Given below is the list of patents protecting Golodirsen, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vyondys 53 | USRE47691 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2028 | Sarepta Theraps Inc |
| Vyondys 53 | US10227590 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Vyondys 53 | US10266827 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Vyondys 53 | US10421966 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Vyondys 53 | US10968450 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Vyondys 53 | US10995337 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Vyondys 53 | US9024007 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Vyondys 53 | US9994851 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Vyondys 53 | US10533174 | Splice-region antisense composition and method |
May 04, 2021
(Expired) | Sarepta Theraps Inc |
| Vyondys 53 | US9416361 | Splice-region antisense composition and method |
May 04, 2021
(Expired) | Sarepta Theraps Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Golodirsen's patents.
Latest Legal Activities on Golodirsen's Patents
Given below is the list recent legal activities going on the following patents of Golodirsen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Withdrawal of Application for PTE Critical | 07 Mar, 2024 | US9024007 |
| Withdrawal of Application for PTE Critical | 07 Mar, 2024 | US10421966 |
| Withdrawal of Application for PTE Critical | 07 Mar, 2024 | US9994851 |
| Withdrawal of Application for PTE Critical | 07 Mar, 2024 | US10266827 |
| Withdrawal of Application for PTE Critical | 07 Mar, 2024 | US10227590 |
| Notice of Final Determination -Election Required | 18 Jul, 2023 | US10266827 |
| Notice of Final Determination -Election Required | 18 Jul, 2023 | US10421966 |
| Notice of Final Determination -Election Required | 18 Jul, 2023 | US9024007 |
| Notice of Final Determination -Election Required | 18 Jul, 2023 | US10227590 |
| Notice of Final Determination -Election Required | 18 Jul, 2023 | US9994851 |
Golodirsen's Family Patents
